Concerning target therapy strategies, tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors currently have limited data and should be investigated in patients with histology other than ccRCC [33]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.